Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 10/20 | 0.71 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4378777 | 0.84 | FOLH1 (0.77) | FOLH1PPARAMRGPRX4TP53POLB | |
| SCHEMBL4374230 | 0.83 | FOLH1 (1.00) | FOLH1PPARAMRGPRX4TP53HTT | |
| SCHEMBL4369616 | 0.82 | FOLH1 (0.67) | FOLH1PPARAMRGPRX4ABCB1 | |
| SCHEMBL4366840 | 0.81 | FOLH1 (0.68) | FOLH1PPARAMRGPRX4 | |
| SCHEMBL13979858 | 0.79 | FOLH1 (0.71) | FOLH1MRGPRX4TP53HTT | |
| SCHEMBL4376266 | 0.78 | PPARA (0.67) | FOLH1PPARA | |
| SCHEMBL4367224 | 0.76 | FOLH1 (0.68) | FOLH1MRGPRX4 | |
| SCHEMBL7041129 | 0.76 | FOLH1 (0.72) | FOLH1PPARAMRGPRX4TP53HTT | |
| SCHEMBL4379752 | 0.76 | FOLH1 (1.00) | FOLH1HTR1ADRD2 | |
| SCHEMBL4377625 | 0.75 | FOLH1 (1.00) | FOLH1MRGPRX4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2025666-A2 | Thiolalkyl benzoic acid derivatives | MGI GP, Inc. (US) | 2009-02-18 | — | — | EP | claimed |
| EP-1406867-B1 | THIOLALKYL BENZOIC ACID DERIVATIVES | GUILFORD PHARM INC (US) | 2008-12-31 | — | — | EP | claimed |
| US-7220780-B2 | Naaladase inhibitors for treating retinal disorders and glaucoma | GUILFORD PHARMACEUTICALS INC. (US) | 2007-05-22 | — | — | US | claimed |
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | GUILFORD PHARMACEUTICALS INC. | 2004-09-23 | — | — | US | claimed |
| WO-2004078180-A2 | NAALADASE INHIBITORS FOR TREATING OPIOID TOLERANCE | GUILFORD PHARMACEUTICALS INC. (US) | 2004-09-16 | — | — | WO | claimed |
| US-6740777-B2 | MERCAPTOALKYL BENZOIC ACID DERIVATIVE ARE USEFUL FOR INHIBITING NAALADASE (ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE/N-/) ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. | 2004-05-25 | — | — | US | claimed |
| US-20030100607-A1 | Mercaptoalkyl benzoic acid derivative are useful for inhibiting NAALADase (acetylated alpha-linked acidic dipeptidase/N-/) enzyme activity | EISAI INC. | 2003-05-29 | — | — | US | claimed |
| EP-1292601-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2003-03-19 | — | — | EP | claimed |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | EISAI INC. | 2003-02-20 | — | — | US | claimed |
| WO-2001092274-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | claimed |
| EP-2025666-A2 | Thiolalkyl benzoic acid derivatives | MGI GP, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-2025666-A2 | Thiolalkyl benzoic acid derivatives | MGI GP, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-1406867-B1 | THIOLALKYL BENZOIC ACID DERIVATIVES | GUILFORD PHARM INC (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-1406867-B1 | THIOLALKYL BENZOIC ACID DERIVATIVES | GUILFORD PHARM INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| WO-2004078180-A2 | NAALADASE INHIBITORS FOR TREATING OPIOID TOLERANCE | GUILFORD PHARMACEUTICALS INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| US-6740777-B2 | MERCAPTOALKYL BENZOIC ACID DERIVATIVE ARE USEFUL FOR INHIBITING NAALADASE (ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE/N-/) ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. | 2004-05-25 | — | — | US | disclosed |
| EP-1292601-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | EISAI INC. | 2003-02-20 | — | — | US | disclosed |
| WO-2001092274-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100607-A1 | Mercaptoalkyl benzoic acid derivative are useful for inhibiting NAALADase (acetylated alpha-linked acidic dipeptidase/N-/) enzyme activity | NAALAD2, DNPEP, ALDH7A1 | FOLH1 14/4885PPARA 1551/4885MRGPRX4 2900/4885 |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | FOLH1 1/4885PPARA 361/4885MRGPRX4 1296/4885 |
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | OPRD1, OPRK1, OPRM1 | FOLH1 254/4885PPARA 3280/4885MRGPRX4 741/4885 |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | ALDH1A2, GAA, PDE6A | FOLH1 124/4885PPARA 3212/4885MRGPRX4 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.